Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Real-World Data

iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics

The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts…

Date: 15th September 2023

T-cell lymphoma highlights at ASH 2022: unmet needs, clinical trial updates & future outlooks

The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA,…

Date: 20th January 2023

Myeloma highlights at ASH 2022: improving access to CAR-T therapy & future outlooks

The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans,…

Date: 3rd January 2023

iwNHL Session IV: T-cell therapies for NHL: CAR-T therapies & third-party EBV T-cells

The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in…

Date: 30th November 2022

CAR-T and lymphoma treatment in the UK

Lymphoma treatment has seen many recent advances, with CAR-T therapy being a game changer for patients. Several clinical trials investigating…

Date: 27th May 2022

ASH 2021: the future of cell therapies in lymphoma

Cell therapies including chimeric antigen receptor (CAR) T-cell therapy represent novel treatments for patients with lymphoma, especially for those who…

Date: 25th February 2022

EHA 2021: real-world data on myeloma, lymphoma and CLL

Real-world data gained through scientific studies is essential in the advancement of treatments for all hematological malignancies. Historically, pharmaceutical companies…

Date: 25th August 2021

Post-ASH Amyloidosis Session from VJHemOnc

The most common form of amyloidosis, light-chain (AL) amyloidosis, results from abnormalities in plasma cells causing them to produce abnormal…

Date: 13th April 2021

The CLL Sessions: highlights from ASH 2020

Chronic lymphocytic leukemia (CLL), also known as B-cell CLL (B-CLL) is the most common leukemia in Europe and North America….

Date: 17th March 2021

The Myeloma Sessions: key updates from ASH 2020

Over the last decades, a deeper understanding of multiple myeloma’s complex pathobiology has transformed the diagnosis, prognosis, and treatment paradigm,…

Date: 22nd February 2021

Advances in the amyloidosis space: Prognostic factors, CAEL-101 immunotherapy and real-world data

Amyloidosis is the name attributed to a group of diseases caused by the extracellular accumulation of amyloid, an abnormal, insoluble…

Date: 5th February 2021

Developments in CLL: MRD, LOXO-305 and venetoclax at ASH 2020

Chronic Lymphocytic Leukemia (CLL) is a B-cell malignancy, predominantly affecting the elderly, which is characterized by an accumulation of immunologically…

Date: 28th January 2021